COLORADO SPRINGS, Colo.,
March 11, 2015 /PRNewswire/
-- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. company
specializing in the development of cannabis-based medicine, called
today's introduction of a United
States Senate bill that would end the federal ban on medical
marijuana "a science-based blessing for patients across
the United States" and a "common
sense move that will contribute to significant new science-based
research."
United States Senator Rand Paul
CARERS Act Press Release:
http://www.paul.senate.gov/?p=press_release&id=1310
The bi-partisan bill was introduced at a press conference by
Senators Rand Paul (R-Ky.),
Cory Booker (D-N.J.), and
Kirsten Gillibrand (D-N.Y.). It
would also downgrade medical marijuana's Drug Enforcement Agency
classification from Schedule 1 to Schedule 2, allowing doctors to
recommend its use to some patients like veterans in need, enable
more research, and ease banking issues in providing services to the
industry. "The emotion of this tugs at your heart," said Sen.
Paul.
"This is a medical treatment that has a medical effect," Sen.
Gillibrand said of one cannabinoid medicine used to relieve a
girl's seizures – hundreds each day. "And we should not have
parents fearing that Child Services is going to be knocking on
their door for trying to help their suffering children."
"This is history," said Raymond C.
Dabney, Director, President & CEO and Co-Founder of
Cannabis Science. "This is our best chance yet to get on with the
work of relieving the suffering of children and veterans and
patients across the United States.
This legislation needs to see the light of day to encourage
research, to bring investment into the field and to help beneficial
medicines to get to the people who need them as quickly as
possible."
The recorded press conference announcing the bill's introduction
can be viewed here at this link:
https://www.youtube.com/watch?v=YTPi5lpXqOE (It begins at
32:37)
Added Dabney, "I highly recommend watching the press conference
video because you will see just how great the medical need is
– you'll hear it directly from patients and parents, including a
woman who suffered from nausea, insomnia and neuralgia, who said,
'Finally I have a medicine that answered my prayers.'"
The press conference also included patients who said they were
able to get relief from medical cannabis while avoiding much
stronger and addictive narcotics, a mother of a child seeking
relief from severe epilepsy, and a military veteran who said that
because of state law, he is a father, a husband, an employee "and a
criminal in the eyes of the Commonwealth of Virginia."
In a joint statement, the sponsors said the legislation, called
the Compassionate Access, Research Expansion and Respect States
(CARERS) Act, would "allow patients, doctors and
businesses in states that have already passed medical marijuana
laws to participate in those programs without fear of federal
prosecution."
Dabney said that if the bill becomes law, legitimate companies
pursuing science-based cannabinoid treatments for disease would
feel more free to pursue their research, as would independent
scientists and physicians – who in many cases risk prosecution and
loss of their livelihoods in order to help suffering patients.
"Some states are more progressive than others, and so patients
and the industry must demand leadership from the top," Dabney said.
"Public opinion and science are on our side."
In December, Congress approved an amendment that bars the
Justice Department from using its funds to prevent states from
implementing their medical marijuana laws — a significant victory
for proponents of the practice. Medical marijuana has been approved
to varying degrees in 23 states and D.C.
About Cannabis Science, Inc.
Cannabis Science, Inc.,
takes advantage of its unique understanding of metabolic processes
to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of
years, and currently, there are a growing number of peer-reviewed
scientific publications that document the underlying biochemical
pathways that cannabinoids modulate. The company works with leading
experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel
therapeutic approaches.
Forward-Looking Statements
This Press Release
includes forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Act of 1934. A statement containing words such as "anticipate,"
"seek," intend," "believe," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science,
Inc., does not undertake any duty nor does it intend to update the
results of these forward-looking statements.
Media Contacts:
VAN STONE PUBLICITY
Carrol Van
Stone
carrol@vanstonepublicity.com
Tel: 304-671-0244
Cannabis Science, Inc.
Raymond
C. Dabney
President & CEO, Co-Founder
info@cannabisscience.com
Tel: 1.888.889.0888
Chad S. Johnson, Esq.
Director, COO & General Counsel
info@cannabisscience.com
Tel: 1.888.889.0888
www.cannabisscience.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-cbis-applauds-historic-step-forward-for-nations-suffering-patients-as-us-senate-introduces-a-medical-marijuana-bill-to-end-federal-prohibition-300048867.html
SOURCE Cannabis Science, Inc.